Hot Prefered Stocks To Own Right Now

Hot Prefered Stocks To Own Right Now: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional ! diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in N e w Brunswick, New Jersey.

Advisors' Opinion:

• [By Anna Prior]

  Johnson & Johnson sa(JNJ)id Tuesday that its second-quarter earnings grew as sales of the company’s new hepatitis C drug continued to boost the health-care giant’s revenue.

• [By Jayson Derrick]

  This morning, Johnson & Johnson (NYSE: JNJ) reported its second quarter results. The company announced an EPS of $1.66, beating the consensus estimate of $1.55. Revenue of $19.49 billion beat the consensus estimate of $18.94 billion. Net earnings for the quarter rose to $4.33 billion from $3.83 billion in the same quarter a year ago as the company saw gains in its major categories. Pharmaceutical sales rose 21.1 percent year over year to $8.509 billion while Medical Devices & Diagnostics saw a 0.7 percent gain in revenue to $7.242 billion, while revenue from Consumer goods rose 2.4 percent to $3.74 billion. Johnson & Johnson saw its gross margin rate decline 0.4 percent to 69.0 percent. The company raised its full year EPS guidance to a range of $5.85 to $5.92 from a previous range of $5.80 to $5.90. Shares lost 1.99 percent, closing at $103.28.

• [By Melvin Backman]

  Strong sales of staples like Tylenol and Motrin helped Johnson & Johnson (JNJ)hit record quarterly revenues in the spring, beating Wall Street expectations.

• [By Ben Levisohn]

  It’s been a painful day for most biotech stocks after Janet Yellen said that smaller ones look pricey. And even Gilead Sciences (GILD) has plunged, despite the fact that Johnson & Johnson (JNJ) earnings hinted at big sales for hepatitis C drug Sovaldi.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-prefered-stocks-to-own-right-now.html